Welcome to our dedicated page for Sanara MedTech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Sanara MedTech Inc. Chief Financial Officer Elizabeth B. Taylor reported a tax-related share disposition tied to vesting of restricted stock. On the vesting of 1,794 restricted shares, the company withheld 437 shares of common stock at $19.90 per share to cover tax withholding obligations.
The footnote clarifies that no shares were issued or sold on the open market; the shares were retained by the company to satisfy taxes. After this withholding transaction, Taylor directly owns 4,945 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Controller Ashley M. Mackey reported a tax-related share disposition. The company withheld 149 shares of common stock at $19.90 per share to cover tax obligations tied to the vesting of 502 restricted shares. After this withholding, Mackey directly owns 2,263 common shares.
Baird Trust Company, Baird Financial Corporation, and Baird Financial Group, Inc. report significant ownership of Sanara MedTech Inc. common stock. The filing shows beneficial ownership of 760,293 shares, representing 8.5% of the company’s common stock, calculated against 8,901,903 shares outstanding as of March 18, 2025.
The shares are held in client accounts over which Baird Trust has investment discretion or voting authority, and the reporting persons state they are holding the securities in the ordinary course of business, not to change or influence control of Sanara MedTech.
Sanara MedTech Inc. filed a current report to let investors know it has released a press release with certain preliminary financial results for the fourth quarter and full year 2025. The company states that this press release, dated January 23, 2026, is provided as an exhibit to the report and is incorporated by reference.
The company also clarifies that the information in this report, including the press release, is being furnished rather than filed, which means it is not subject to certain liability provisions of the securities laws or automatically incorporated into other securities filings unless specifically referenced.
Sanara MedTech Inc. (SMTI) reported that it is furnishing an investor presentation as Exhibit 99.1 to a current report on Form 8-K. The presentation will be used in meetings with investors and analysts, including during the company’s appearance at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. The deck outlines the company’s priorities and strategy for the 2026 fiscal year and is intended to be read together with its other SEC filings and public announcements. The company states that this information is being furnished under Regulation FD, is not deemed “filed” under the Exchange Act, and is not automatically incorporated by reference into other Securities Act or Exchange Act filings.
Sanara MedTech Inc. (SMTI) reported stronger continuing operations for the quarter ended September 30, 2025. Net revenue rose to $26,333,819 from $21,671,599 a year ago, led by soft tissue repair products ($23,424,126) and bone fusion products ($2,909,693). Gross profit increased to $24,459,605, and operating income from continuing operations improved to $2,941,240 versus $778,537 last year. Continuing operations posted net income of $834,493 in Q3 and $714,186 year‑to‑date.
The company discontinued its THP segment in mid‑September and recorded an asset impairment charge of $26,472,407, driving Q3 net loss to $(30,412,108) and year‑to‑date net loss to $(35,957,889). Cash was $14,939,646 with positive operating cash flow of $2,841,568 for the nine months. Long‑term debt increased to $45,089,787, contributing to higher interest expense ($1,818,105 in Q3). Shareholders’ equity declined to $6,140,534. As of November 11, 2025, 8,935,657 common shares were outstanding.
Sanara MedTech Inc. (SMTI) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The company furnished this information on a Form 8-K dated November 12, 2025, with the press release included as Exhibit 99.1.
The submission states that the press release and related information are furnished and not deemed “filed” under Section 18 of the Exchange Act, which limits associated liabilities. SMTI’s common stock trades on the Nasdaq Capital Market under the symbol SMTI.
Sanara MedTech Inc. (SMTI) disclosed a business update, announcing a strategic realignment that includes discontinuing operations of its Tissue Health Plus. The company communicated this decision via a press release issued on November 11, 2025, which is furnished as Exhibit 99.1.
The press release is provided for information purposes and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference into other filings unless expressly stated.
Sanara MedTech Inc. (SMTI) reported a grant of restricted common stock to CEO Seth D. Yon. The Form 4 shows the reporting person was granted 28,563 restricted shares on 09/15/2025 at no cash price, increasing his beneficial ownership to 89,851 shares. The restricted stock award was made under the company's 2024 Omnibus Long-Term Incentive Plan and vests in three equal installments on 09/15/2026, 09/15/2027 and 09/15/2028, contingent on continued employment through each vesting date. The filing is a routine Section 16 disclosure documenting the grant and resulting ownership position.
Sanara MedTech Inc. (SMTI) Form 3 shows Ashley M. Mackey reported beneficial ownership of 2,412 shares of the issuer's common stock. The report cites an event date of 08/29/2025 and the form is signed on 09/04/2025. The filing identifies the reporting person as a Director and indicates Controller in the relationship field. No derivative securities or additional holdings are reported.